Prognostic markers in gliomas.
Future Oncol
; 6(5): 733-9, 2010 May.
Article
en En
| MEDLINE
| ID: mdl-20465388
ABSTRACT
In recent years, extensive molecular studies have identified diagnostic and prognostic markers in gliomas that reinforce the WHO histological classification. 1p19q codeletion, O(6)-methylguanine DNA methyltransferase (MGMT) status, and mutations of isocitrate dehydrogenases 1 and 2 (IDH1/IDH2) are currently the three most pertinent markers in diffuse gliomas. Ongoing clinical trials already stratify or select patients according to their 1p19q codeletion or MGMT status. Mutations of IDH1 have been recently identified as a major prognostic factor in diffuse gliomas. Future studies should determine whether IDH1/IDH2 mutations are predictive of response to treatments. Routine use of these markers considerably contributes to a more objective classification of gliomas based on both histological and molecular features.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Encefálicas
/
Biomarcadores de Tumor
/
Glioma
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Future Oncol
Año:
2010
Tipo del documento:
Article
País de afiliación:
Francia